In an unprecedented event, an all-female lineup of advocates is set to argue a high-profile Supreme Court case centered on the availability of the abortion pill mifepristone. Notably, this is a rarity for the US Supreme Court, where male attorneys significantly outnumber their female peers.
The case, which is expected to be one of the most scrutinized of the term, comes amid an increasingly heated debate around abortion rights and availability of abortion drugs. Mifepristone, the drug in question, is currently available through a healthcare provider in a clinic, medical office, or hospital, under the FDA’s Risk Evaluation and Mitigation Strategy (REMS).
The legal argument centers on whether the REMS requirement for in-person dispensing should continue in the era of telemedicine and amidst the COVID-19 pandemic which has raised concerns about unnecessary exposure risks.
It is yet to be seen whether the unique all-female lineup of advocates will have any influence on the proceedings or decision of the case. What is clear, however, is the confluence of several significant issues: a pivotal Supreme Court case, the increasing prominence of women in the legal profession, and the ongoing debate over reproductive rights and healthcare access.
For more detailed information, please visit the original news article here.